Bevacizumab in metastatic breast cancer: when may it be used?-Reference-Cited by-同舟云学术

Bevacizumab in metastatic breast cancer: when may it be used?

Published:2011-02-07 Issue:2 Volume:3 Page:85-93
ISSN:1758-8359
Container-title:Therapeutic Advances in Medical Oncology
language:en
Short-container-title:Ther Adv Med Oncol

Author:

Goldfarb Shari B.¹,Hudis Clifford²,Dickler Maura N.³

Affiliation:

1. Memorial Sloan-Kettering Cancer Center, Medicine and Epidemiology and Biostatistics, New York, NY, USA

2. Memorial Sloan-Kettering Cancer Center, Medicine, New York, NY, USA

3. Memorial Sloan-Kettering Cancer Center, Breast Cancer Medicine Service, 300 East 66th Street, New York, NY 10065, USA

Abstract

Tumor angiogenesis, which is necessary for breast cancer growth, invasion and metastases, is regulated by pro-angiogenic factors such as vascular endothelial growth factor (VEGF). Bevacizumab is a recombinant humanized monoclonal antibody that targets VEGF. The addition of bevacizumab to chemotherapy has improved progression-free survival in the first- and second-line treatment of patients with advanced-stage breast cancer. In this article we review the clinical trials testing the utility of bevacizumab for the treatment of metastatic disease.

Publisher

SAGE Publications

Subject

Oncology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1758834010397627

Reference33 articles.

1. Acute Temporal Regulation of Vascular Endothelial Growth/Permeability Factor Expression and Endothelial Morphology in the Baboon Endometrium by Ovarian Steroids

2. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation;Drug Delivery and Translational Research;2024-07-15

2. Decellularized plant-derived vasculature-on-a-chip interacting with breast cancer spheroids to evaluate a dual-drug therapy;Applied Materials Today;2024-02

3. Monoclonal antibodies in breast cancer: A critical appraisal;Critical Reviews in Oncology/Hematology;2023-03

4. Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review;Frontiers in Medicine;2022-04-12

5. A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma;Cancer Chemotherapy and Pharmacology;2020-11-19